This article is more than 5 years old. Information may no longer be current.

Adverum Biotechnologies receives fast track designation for wet AMD therapy

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA granted fast track designation for ADVM-022, a novel gene therapy candidate for the treatment of wet age-related macular degeneration, according to a press release from Adverum Biotechnologies.

ADVM-022 utilizes a proprietary vector capsid carrying an aflibercept coding sequence under the control of a proprietary expression cassette, the release said. The treatment is administered as a single intravitreal injection.

An open-label, multicenter phase 1 dose-escalation trial will assess the safety and tolerability of ADVM-022 in patients with wet AMD who are responsive to anti-VEGF treatment.

“The FDA’s fast track designation is an important recognition of our ADVM-022 gene therapy program,” Leone Patterson, interim president and CEO of Adverum, said in the release. “We look forward to working with the FDA and benefiting from the potential expedited development and regulatory path offered by their fast track program.”